FOXC2 and liver cancer: Specifically, it was a metabolic regulation at the systemic level, in which the BHB-Glow medium hindered FOXC2 expression by interfering with glycolytic metabolism and inhibiting insulin production, thereby inhibiting liver cancer cells’ malignant progression.